We read with interest the article by Weinreich and colleagues.
We read with interest the article by Weinreich and colleagues. 1 They showed that transgenic mice born to mothers aged 8 months or older had a significantly lower frequency of murine ankylosing enthesopathy than mice born to younger mothers. They speculated that an age related increase in maternal antibody levels resulted in increasing protection of oVspring against a ubiquitous, potentially arthritogenic, micro-organism. In humans, as in the mouse model, environmental factors must influence the development of ankylosing spondylitis (AS). We sought evidence that the age of conception in women with AS influenced the risk of their oVspring developing disease.
We collected data from 3473 patients with AS, regarding the age, and AS status, of relatives. Nine hundred and sixty two were female, male: female ratio 2.6:1. Six hundred and sixty five were recruited from the Royal National Hospital for Rheumatic Diseases (RNHRD), 2779 from the National Ankylosing Spondylitis Society (NASS), and 29 were relatives of RNHRD patients or NASS members, but were not RNHRD patients or NASS members themselves. Those from the RNHRD have been confirmed, by a rheumatologist, as having AS according to the New York criteria. 2 The diagnosis of AS in the overall patient population has been validated in three separate cohorts in which 100% of 146 patients had AS (personal communications M Brown, Oxford), 92.7% of 330 patients had AS (personal communications K Gomez, Bath), and 96% of 50 patients had AS. 3 Data were available for 39 pairs in which both mother and oVspring had AS (21 mother:daughter pairs, 18 mother:son pairs). There were no families with data available for more than one mother:child pair. The higher than expected ratio of mother:daughter to mother:son pairs is the subject of an ongoing investigation. From our data base we chose 39 control pairs, where the mother had AS and the oVspring did not, by matching the oVspring for sex and age to the nearest year. We were able to match the oVspring for birth rank in 37 cases (20 mother:daughter pairs, 17 mother:son pairs). The oVspring were not matched for sibship size. The maternal ages at birth of oVspring are shown (see table 1 ). Using paired t tests, we compared maternal ages at childbirth in the groups where the oVspring had AS, and where the oVspring did not have AS. The diVerence in the maternal age at childbirth was significant only when comparing mothers of sons with AS and mothers of sons without AS (p = 0.04; diVerence in mean maternal age at childbirth = 2.78 years). Mothers with AS, whose sons had AS, had given birth at a older age than those whose sons did not have AS.
Unlike the situation in the murine model, we find no evidence that increasing maternal age in humans is protective against the development of AS. However, the number of pairs available for our analysis was small. The influence of age at conception, on the development of AS in the oVspring, remains an interesting area that deserves further attention. KARIM 
LETTER TO THE EDITOR

Methotrexate and triamterene-a potentially fatal combination?
A 57 year old woman had been treated for several years with diclofenac 150 mg/day, atenolol 50 mg/day, and triamterene/ hydrochlorthiazide 50/25 mg/day for rheumatoid arthritis (RA) and hypertension. Her doctor started treatment with methotrexate 5 mg/week for active RA. At the start of methotrexate treatment her full blood count was normal except for a haemoglobin of 10.1 g/dl. Renal and liver function were not checked. She weighed 68.5 kg. After one month her haemoglobin had fallen to 8.0 g/dl and her white cell count to 3.6 × 10 9 /l and she developed mouth ulcers, dyspnoea, and easy bruising. She continued taking methotrexate, but after a month of these symptoms was admitted to hospital as an emergency.
On examination she was pale, tachypnoeic, and dehydrated with extensive mucosal ulceration. Investigations showed a pancytopaenia with renal impairment (Hb 4.1 g/dl, mean cell volume 89.5 fl, white cell count 3.1 × 10 9 /l, neutrophils 2.0 × 10 9 /l, lymphocytes 0.5 × 10 9 /l, platelets 31 × 10 9 /l, serum urea 20.8 mmol/l, and creatinine 148 µmol/l). Urine analysis, liver function tests, and chest x ray were unremarkable. Plasma folate was low at 1.6 µg/l (reference range 1.9-9.0). Cultures of body fluids were subsequently sterile. She was treated for presumed methotrexate induced bone marrow suppression, with blood products and antimicrobials, discontinuation of usual medication, and, on haematological advice, oral folic acid 10 mg/day. Her white cell count fell over the next 48 hours (2.2 × 10 9 /l, neutrophils 1.3 × 10 9 /l), and a bone marrow biopsy showed features consistent with partially treated methotrexate induced megaloblastosis. Oral folinic acid 15 mg four times daily was substituted for folic acid and five days later her full blood count and renal function had returned to normal (Hb 10.5 g/dl, white cell count 6.1 × 10 9 /l, platelets 268 × 10 9 /l, serum urea 2.8 mmol/l, and creatinine 90 µmol/l).
Methotrexate is a folate antagonist, competing with folate for active transport into cells and competitively inhibiting dihydrofolate reductase (DHFR). The risk of marrow toxicity may be increased by co-prescribing other folate antagonists. 1 Triamterene is a potassium sparing diuretic, structurally similar to folate, with anti-folate activity. It inhibits DHFR in vivo 2 and in vitro 3 and inhibits folic acid absorption in the rat. 4 Patients treated with high doses of triamterene for ascites may develop megaloblastic anaemia, which responds to folinic acid treatment. [3] [4] [5] Thus, there are good theoretical reasons for this patient developing marrow toxicity as a result of an interaction between methotrexate and triamterene. Long term triamterene treatment may have rendered her folate deficient, the two drugs may have had a synergistic eVect on DHFR, or both of these mechanisms may have been involved.
The lack of information on pre-treatment renal function means that the possibility that toxicity developed as a result of reduced renal clearance of methotrexate cannot be excluded. Hypertension or the combination of medication may have resulted in compromised renal function. However, the fact that the serum urea was increased out of proportion to the creatinine, and both parameters returned to normal with rehydration suggests that her abnormal renal function may have been secondary to dehydration consequent upon her illness, rather than the cause of it.
In addition to this suspected drug interaction, this case highlights several other important points about the prescribing of methotrexate. It should be given under specialist supervision with baseline and regular monitoring of full blood count, renal and liver function. 6 The patient and doctor should be warned about possible side eVects and advised to stop the drug should suspected side eVects develop. Extra caution is required in patients with renal impairment 7 or receiving nephrotoxic drugs. 1 Finally folic acid has no place in the management of methotrexate induced pancytopaenia, the reduced form of folate, folinic acid, should be given as soon as the condition is suspected. 
